An underground economy for unlicensed slimming drugs is being driven by TikTok fitness influencers and vendors on messaging platforms, according to new investigations.
Experimental Drug Gaining Traction Via Social Media
Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing properties. Followers are encouraged to message these profiles privately for supplier links, while also obtaining promotional offers.
Active Trade on Social Networks
Additionally, a robust market exists on Telegram, where communities with thousands of members share comparison images, administration instructions and assertions of next-day British shipping. Sellers promote the drug there before redirecting buyers to WhatsApp for purchases.
Learning About The Experimental Drug
This medication is an experimental injection created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted digitally as the next Ozempic.
Healthcare Professionals Voice Concerns
However, doctors and chemists have warned that the distribution of what is still an unapproved medication in the United Kingdom is a cause for concern and could lead to individuals injecting products of uncertain source.
Several experts said the popularity for retatrutide could be connected to the increasing price of approved slimming treatments such as Mounjaro.
Legal Position and Enforcement
Selling retatrutide on social media or messaging apps is illegal in the UK, as it is an unlicensed drug that must not be promoted or distributed for personal consumption under the British medical regulations.
Some content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still breach medicines, advertising, and consumer laws, potentially leading to fines, prosecution or imprisonment.
Service Response and Material Elimination
According to the social media company, the platform has taken down problematic content and prohibited associated keywords and search suggestions. The company stated it was committed to maintaining the platform secure and investing in strengthening compliance measures.
Digital Marketplace Activities
Investigations also discovered communities with up to 9,000 participants selling retatrutide using the platform's integrated discovery tool, which functions like a public directory. Typing “retatrutide” instantly displays groups with numerous of users, filled with photos of slimming results, glowing reviews and detailed guides for mixing or administering at residence.
Within minutes of joining one group, a vendor posted contact information, where the majority of purchases occur. The seller sent an guidebook and guaranteed delivery within two days. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about weight, medical conditions or past usage.
Product Details and Pricing
Inside these groups, messages show black plastic packages with Royal Mail stickers, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, mixed at residence with purified liquid, or ready-to-use injectors usually priced at £160 for 20 milligrams. When questioned how much time a injector should be used, sellers give contradictory answers varying between a several days to “depends on your body”.
Platform Oversight and Safety Actions
A spokesperson for the messaging service said it actively monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are injecting substances they can’t verify. Although the research behind retatrutide is sound, these online versions may not include what they claim,” stated a pharmacy expert, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With costs increasing, individuals are using online platforms. But fake treatments are highly risky. You can’t be certain what’s contained or whether the conditions they were produced in was sterile,” she said.
Her staff has already seen patients injured by self-injection from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” said the doctor. “These substances could be impure or incorrectly dosed.”
Producer Statement
A spokesperson from the pharmaceutical company said the substance was in third stage clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company investigational product not yet approved … may expose users to potentially serious health risks”.
